Chloe, a 2019 CCB fellow, is a post-doctoral researcher in the Addiction Biology Unit of the Molecular Targets and Medications Discovery Branch at the National Institute on Drug Abuse Intramural Research Program. As a CCB Fellow, Chloe will study the role of the dopamine D3 receptor, specifically in the insular cortex, in mediating both opioid abuse and analgesia. These investigations are based on her discoveries that dopamine D3 receptor antagonists paradoxically reduce opioid reward while augmenting analgesia, and that D3 receptors are strongly expressed in the insular cortex, a region of the brain whose dysfunction is implicated in compulsive drug abuse as well as pain sensation. By disentangling the neural substrates linking opioids’ addictive liability with their clinical utility, Chloe aims to generate fresh insights into new and more precise therapeutics for both addiction and pain.
Chloe received her Ph.D. from Boston University in Boston, Massachusetts, where she studied comorbid attention-deficit/hyperactivity disorder and cocaine abuse in rodent models. She then moved to McLean Hospital/Harvard Medical School, where she investigated neurodevelopmental risk factors and preventative interventions for adolescent cocaine use. Chloe joined the NIDA-IRP in 2017. Her current research interests include dissecting cell type-specific neural circuits underlying drug (cannabis, cocaine, and opioid) reward and aversion using transgenic and optogenetic approaches, and neurochemical mechanism-driven medication development for the treatment of substance use disorders.